Antitumor Activity of Rat Mesenchymal Stem Cells during Direct or Indirect Co-Culturing with C6 Glioma Cells


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription Access

Abstract

The tumor-suppressive effect of rat mesenchymal stem cells against low-differentiated rat C6 glioma cells during their direct and indirect co-culturing and during culturing of C6 glioma cells in the medium conditioned by mesenchymal stem cells was studied in an in vitro experiment. The most pronounced antitumor activity of mesenchymal stem cells was observed during direct co-culturing with C6 glioma cells. The number of live C6 glioma cells during indirect co-culturing and during culturing in conditioned medium was slightly higher than during direct co-culturing, but significantly differed from the control (C6 glioma cells cultured in medium conditioned by C6 glioma cells). The cytotoxic effect of medium conditioned by mesenchymal stem cells was not related to medium depletion by glioma cells during their growth. The medium conditioned by other “non-stem” cells (rat astrocytes and fibroblasts) produced no tumor-suppressive effect. Rat mesenchymal stem cells, similar to rat C6 glioma cells express connexin 43, the main astroglial gap junction protein. During co-culturing, mesenchymal stem cells and glioma C6 cells formed functionally active gap junctions. Gap junction blockade with connexon inhibitor carbenoxolone attenuated the antitumor effect observed during direct co-culturing of C6 glioma cells and mesenchymal stem cells to the level produced by conditioned medium. Cell–cell signaling mediated by gap junctions can be a mechanism of the tumor-suppressive effect of mesenchymal stem cells against C6 glioma cells. This phenomenon can be used for the development of new methods of cell therapy for high-grade malignant gliomas.

About the authors

A. N. Gabashvili

Department of Medical Nanobiotechnologies, Medico-Biological Faculty, N. I. Pirogov National Research Medical University

Author for correspondence.
Email: gabashvili.anna@gmail.com
Russian Federation, Moscow

V. P. Baklaushev

Department of Medical Nanobiotechnologies, Medico-Biological Faculty, N. I. Pirogov National Research Medical University; Federal Research-and-Clinical Center, Federal Medico-Biological Agency

Email: gabashvili.anna@gmail.com
Russian Federation, Moscow; Moscow

N. F. Grinenko

Department of Fundamental and Applied Neurobiology, V. P. Serbsky Federal Medical Research Center of Psychiatry and Narcology, Ministry of Health of the Russian Federation

Email: gabashvili.anna@gmail.com
Russian Federation, Moscow

P. A. Mel’nikov

Department of Medical Nanobiotechnologies, Medico-Biological Faculty, N. I. Pirogov National Research Medical University

Email: gabashvili.anna@gmail.com
Russian Federation, Moscow

S. A. Cherepanov

Department of Medical Nanobiotechnologies, Medico-Biological Faculty, N. I. Pirogov National Research Medical University

Email: gabashvili.anna@gmail.com
Russian Federation, Moscow

A. B. Levinsky

Department of Medical Nanobiotechnologies, Medico-Biological Faculty, N. I. Pirogov National Research Medical University

Email: gabashvili.anna@gmail.com
Russian Federation, Moscow

V. P. Chehonin

Department of Medical Nanobiotechnologies, Medico-Biological Faculty, N. I. Pirogov National Research Medical University; Department of Fundamental and Applied Neurobiology, V. P. Serbsky Federal Medical Research Center of Psychiatry and Narcology, Ministry of Health of the Russian Federation

Email: gabashvili.anna@gmail.com
Russian Federation, Moscow; Moscow


Copyright (c) 2016 Springer Science+Business Media New York

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies